ECSP10010234A - Piperazinas como agentes antiobesidad - Google Patents

Piperazinas como agentes antiobesidad

Info

Publication number
ECSP10010234A
ECSP10010234A EC2010010234A ECSP10010234A ECSP10010234A EC SP10010234 A ECSP10010234 A EC SP10010234A EC 2010010234 A EC2010010234 A EC 2010010234A EC SP10010234 A ECSP10010234 A EC SP10010234A EC SP10010234 A ECSP10010234 A EC SP10010234A
Authority
EC
Ecuador
Prior art keywords
piperazinas
compounds
antiobesity agents
preparation
dyslipidemias
Prior art date
Application number
EC2010010234A
Other languages
English (en)
Spanish (es)
Inventor
Michael Higginbottom
Joseph W Boyd
Giles A Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP10010234A publication Critical patent/ECSP10010234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EC2010010234A 2007-12-05 2010-06-04 Piperazinas como agentes antiobesidad ECSP10010234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0702696 2007-12-05

Publications (1)

Publication Number Publication Date
ECSP10010234A true ECSP10010234A (es) 2010-07-30

Family

ID=40409928

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010234A ECSP10010234A (es) 2007-12-05 2010-06-04 Piperazinas como agentes antiobesidad

Country Status (17)

Country Link
US (3) US20110059969A1 (cg-RX-API-DMAC7.html)
EP (1) EP2229362A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011506294A (cg-RX-API-DMAC7.html)
KR (1) KR20100093104A (cg-RX-API-DMAC7.html)
CN (1) CN102026975A (cg-RX-API-DMAC7.html)
AU (1) AU2008333173A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819989A2 (cg-RX-API-DMAC7.html)
CA (1) CA2707555A1 (cg-RX-API-DMAC7.html)
CO (1) CO6280487A2 (cg-RX-API-DMAC7.html)
CR (1) CR11479A (cg-RX-API-DMAC7.html)
DO (1) DOP2010000167A (cg-RX-API-DMAC7.html)
EA (1) EA201000926A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010234A (cg-RX-API-DMAC7.html)
IL (1) IL205874A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010006259A (cg-RX-API-DMAC7.html)
WO (1) WO2009071658A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003976B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093248B2 (en) * 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
KR20100097701A (ko) * 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
US20140005188A1 (en) 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)乙醇的制备方法
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420193A1 (de) * 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
BR9709529A (pt) 1996-06-06 1999-08-10 Smithkline Beecham P L C Socie Fragmentos de leptina (proteína ob)
US6057337A (en) * 1998-02-02 2000-05-02 Shiseido Co., Ltd. 1,2-DI-substituted piperidine derivative, hair growth promoter and external composition for skin using the same
JP2001131149A (ja) 1999-11-08 2001-05-15 Sumitomo Pharmaceut Co Ltd 選択的セロトニン再取り込み阻害剤
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
IL155092A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
MXPA05013365A (es) 2003-06-20 2006-04-05 Arena Pharm Inc Derivados de n-fenil-piperazina y metodos para profilaxis o tratamiento de enfermedades asociadas con el receptor 5ht2c.
US7700597B2 (en) * 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
EP1991211A1 (en) 2006-02-28 2008-11-19 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
KR20100097701A (ko) 2007-12-05 2010-09-03 아스트라제네카 아베 비만 치료제로서의 모르폴린 유도체
KR20100097725A (ko) 2007-12-05 2010-09-03 아스트라제네카 아베 신규 화합물 ⅲ
US8093248B2 (en) 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
JP2011522009A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物vii
JP2011522006A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物v
AU2009254557A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab (Publ) Small molecule leptin receptor modulators
MX2010013359A (es) 2008-06-04 2011-04-07 Astrazeneca Ab Nuevos derivados de piridina como mimeticos moduladores del receptor de leptina.

Also Published As

Publication number Publication date
BRPI0819989A2 (pt) 2015-05-12
EA201000926A1 (ru) 2011-02-28
DOP2010000167A (es) 2010-06-30
CA2707555A1 (en) 2009-06-11
CO6280487A2 (es) 2011-05-20
MX2010006259A (es) 2010-08-23
KR20100093104A (ko) 2010-08-24
US7851471B2 (en) 2010-12-14
US20110059969A1 (en) 2011-03-10
ZA201003976B (en) 2011-04-28
US20110046135A1 (en) 2011-02-24
AU2008333173A1 (en) 2009-06-11
WO2009071658A1 (en) 2009-06-11
EP2229362A1 (en) 2010-09-22
CN102026975A (zh) 2011-04-20
US20090181967A1 (en) 2009-07-16
JP2011506294A (ja) 2011-03-03
CR11479A (es) 2010-07-19
IL205874A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CO6280487A2 (es) Piperazinas como agentes antiobesidad
CR11801A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
UY30470A1 (es) Compuestos heteroarilos de cinco heteroatomos sustituidos con fenilo conteniendo nitrogeno, composiciones farmacéuticas y aplicaciones.
ECSP099452A (es) Derivados de éster y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
CO6470899A2 (es) 2,4-diaminopirimidinas para el tratamiento de enfermedades caracterizadas por proliferación celular excesiva o normal
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
CR9722A (es) Derivados de benzilpiperazina y su uso medico
NI201100117A (es) Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
PA8806801A1 (es) Compuestos de amida como refuerzos de antivirales
ECSP109961A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica
PA8773601A1 (es) Agonistas cannabinoides de bencimidazol
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
UY31143A1 (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
AR053691A1 (es) Agentes endoparasiticidas